The FDA approved Roivant’s oral therapy brepocitinib for dermatomyositis, giving the company its first major regulatory win in the condition. The drug will be marketed as Lisraya and is dosed once daily. For patients, the approval targets a rare autoimmune disease currently managed with high-dose steroids and other immune-suppressing regimens. Roivant’s Priovant subsidiary backed the development, and the decision adds an oral option aimed at reducing reliance on broad immunosuppression.